English | Spanish
ecancer
Login Register
The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+ -
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1721]
News [2697]
Articles [105]
Editorials [3]
Conferences [89]
elearning [4]
EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML
EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant A...
EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations
EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutat...
EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL
EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL
EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma significantly improves PFS
EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-lin...
EHA 2022: Decitabine shows similar survival and fewer adverse events compared to standard chemo in geriatric AML
EHA 2022: Decitabine shows similar survival and fewer adverse events compared to standard chemo in g...
EHA 2022: Quizartinib improves overall survival in adults with FLT3-ITD+ acute myeloid leukaemia
EHA 2022: Quizartinib improves overall survival in adults with FLT3-ITD+ acute myeloid leukaemia
EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma
EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/r...
EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with venetoclax in fit patients with treatment-naïve chronic lymphocytic leukaemia
EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with ...
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Drugs used to treat blood cancer could activate “sleeping” cancer-causing gene
Drugs used to treat blood cancer could activate “sleeping” cancer-causing gene
<12345...270>

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Follow ecancer on Facebook
  • Follow ecancer on Twitter
  • Follow ecancer on Linkedin
  • Subscribe to the ecancer YouTube channel
© 2022 ecancer, all rights reserved
UK registered charity number: 1176307